A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
Condition(s):CancerLast Updated:November 13, 2017Completed
Hide Studies Not Open or Pending
Condition(s):CancerLast Updated:November 13, 2017Completed
Condition(s):GlioblastomaLast Updated:February 24, 2016Unknown status
Condition(s):Solid Tumor, AdultLast Updated:April 22, 2021Completed
Condition(s):Ovarian Sarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaLast Updated:June 24, 2016Completed
Condition(s):Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerLast Updated:December 19, 2018Completed
Condition(s):Breast Cancer; Prostate Cancer; Advanced Solid TumorsLast Updated:May 6, 2023Completed
Condition(s):Adenocarcinoma of the ProstateLast Updated:August 8, 2018Unknown status
Condition(s):Diagnosis of MelanomaLast Updated:December 23, 2014Withdrawn
Condition(s):CancerLast Updated:January 18, 2017Terminated
Condition(s):Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IV Breast CancerLast Updated:August 27, 2015Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.